Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients who develop a blind spot in the middle of their vision due to advanced AMD.

📌 The Core Development

Age-related macular degeneration (AMD) affects more than 5 million people around the world.

Editorial Wire & Sponsor Desk
News Seconds Verified Independent Reporting Network

🔍 Background & Sector Context

And until now, no treatment could restore their vision.

📊 Industry & Real-World Impact

The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that.

⚡ Prefer Visual Stories on Mobile?

Experience this news piece in an interactive 5-slide visual format crafted for mobile devices & Google Discover.

View Web Story ⚡

🔮 Strategic Outlook & What Lies Ahead

It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients who develop a blind spot in the middle of their vision due to advanced AMD.

Editorial Integrity & Multi-Source Notice: News Seconds adheres to rigorous verification and fact-checking protocols. Original reporting credited to MIT Tech Review. For primary wire documentation and full source material, visit Original Coverage at MIT Tech Review ↗.